RxDoctor Payments Data

Cathleen Reitz

Nurse Practitioner · Olathe, KSNPI 1588831663

Payments from drug & device makers

$1,017in general payments, 2019–2025

Across 23 payments — averaging $44.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$209
  • Novartis$178
  • E.r. Squibb & Sons, L.L.C.$165
  • Kestra Medical Technology Services, Inc.$157
  • AstraZeneca$122
  • Amgen$90
  • plus $94 from 3 others

What the payments were for

  • Food & beverage$1,017100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,017 in reported general payments places this provider in the 75th percentile of 1,326 nurse practitioner providers in Kansas.

See all nurse practitioner providers in Kansas

Medicare billing

Part B allowed, 2024
$22,905
Medicare patients
184
Services billed
263

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban127$87,178
FarxigaDapagliflozin Propanediol70$45,190
EntrestoSacubitril/Valsartan48$32,652
XareltoRivaroxaban13$8,972
Ranolazine ErRanolazine16$1,103
Metoprolol Succinate140$1,079
Atorvastatin Calcium144$1,029
Colchicine21$968
ClopidogrelClopidogrel Bisulfate73$684
Potassium Chloride44$581
Bumetanide39$518
Losartan Potassium83$372
Spironolactone76$316
Rosuvastatin Calcium61$292
Furosemide91$258

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$122$45,19070 claims
NovartisEntresto$178$32,65248 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,326 nurse practitioner providers in Kansas.

Other nurse practitioner in Olathe

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →